Preclinical and Clinical Evaluation of Novel Agents for Noninvasive Imaging of Prostate Cancer
Abstract
It is often impossible to optimally plan therapy for prostate cancer as current imaging is unreliable in determining if the cancer has spread beyond the prostate. Similarly, when prostate cancer recurs, as evidenced by a rising serum PSA level, non-invasively determining the precise location of the recurrence is often impossible. We have developed new radioactive compounds, NM404 and NM412, which are radioiodinated phospholipid ether analogs and have shown that they can localize to prostate cancer in rodent models of prostate cancer. We have recently shown that NM404 (1125 labeled) develops tumor uptake 37 times that of normal muscle, 9 times that of normal prostate and 3-11 times that of normal blood and liver, with 18% ID/g in the tumor at 5 days post injection. This level of targeting is considerably higher than most other radiopharmaceuticals. We also have completed pre clinical toxicology tests with the NM404 and NM412 reagents, which have shown no toxicity in doses up to 200 times that of the planned human dose in both rat and rabbit models. Dosimetry calculations for the radio labeled compounds have been completed. These data have allowed for development of protocols to begin human imaging studies, after appropriate approvals are obtained.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1999
- Accession Number
- ADA385690
Entities
People
- Richard L. Wahl
Organizations
- University of Michigan